(P035) Outcomes in Patients With Hypopharyngeal Cancer Treated With Intensity-Modulated Radiation Therapy

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Intensity-modulated radiation therapy (IMRT) is increasingly used in the treatment of hypopharyngeal carcinoma for functional organ-sparing. We retrospectively reviewed our single-institution experience treating stage I–IVa hypopharyngeal cancer (HPC) patients with definitive IMRT +/− chemotherapy.

Mark A. Edson, MD, PhD, Vinita Takiar, MD, PhD, Beth M. Beadle, MD, PhD, Steven J. Frank, MD, PhD, Clifton D. Fuller, MD, PhD, Gary B. Gunn, MD, William H. Morrison, MD, David R. Rosenthal, MD, Adam S. Garden, MD, Jack Phan, MD; UT MD Anderson Cancer Center

Background: Intensity-modulated radiation therapy (IMRT) is increasingly used in the treatment of hypopharyngeal carcinoma for functional organ-sparing. Due to the relative rarity of this diagnosis, particularly at early stages, few reports of outcomes exist. We retrospectively reviewed our single-institution experience treating stage I–IVa hypopharyngeal cancer (HPC) patients with definitive IMRT +/− chemotherapy.

Materials and Methods: Fifty-seven patients who were treated with definitive IMRT from 2003–2013 met our inclusion criteria. The Kaplan-Meier method was used to estimate locoregional control (LRC), distant metastasis-free survival (DMFS), progression-free survival (PFS), and overall survival (OS) of this cohort of patients.

Results: Median age at treatment was 65 years. American Joint Committee on Cancer (AJCC) clinical stages were: I, 1 (T1 N0); II, 12 (10 T2 N0 and 2 T1 N1); III, 15 (6 T2 N1, 4 T3 N0, and 5 T3 N1); and IVA, 29 (5 T1 N2, 13 T2 N2, and 11 T3 N2). Patients were treated to a dose of 66–72 Gy (1.8–2.2 Gy per fraction). Forty-four patients (77%) received chemotherapy: 43 concurrent and 38 induction. The median follow-up was 28.8 months (range: 3–105 mo). The 2- and 5-year OS was 74% and 60%, respectively; LRC, DMFS, and PFS at 2 years were 77%, 88%, and 62%, respectively. There was no significant difference in OS (P = .7) or PFS (P = .4) when comparing patients by AJCC stage or nodal status. However, smaller primary tumors did trend toward improved 2-year OS (86% for T1 vs 72% for T2–T3; P = .2), which was independent of nodal status. There was a trend toward improved LRC in patients who received chemotherapy (P = .07). Three patients had postradiotherapy neck dissection for persistent nodal disease. Feeding tubes (FTs) were placed in 38 patients (67%): 9 prior to treatment (16%), 26 during treatment (46%), and 3 (5%) after treatment. Of those with FTs placed during or after treatment who became FT-independent (97%), median FT duration was 2.8 months (range: 1.2–13.9 mo). Twelve grade 3 toxicities were observed: nine dysphagia, two fatigue, and one pain. Actuarial 2-year and 5-year grade 3 toxicities were 18.4% and 23.2%, respectively.

Conclusions: These preliminary data suggest acceptable disease outcome and toxicity rates for hypopharyngeal carcinoma patients treated with definitive IMRT+/− chemotherapy. Smaller primary size and use of chemotherapy may predict for better prognosis. Further analysis of this cohort and of patients with T4 or N3 disease is ongoing to validate these findings.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content